On November 10, 2021 AbbVie (NYSE: ABBV) and the University of Chicago reported thatt have extended their collaboration agreement through 2025 to support preclinical oncology research (Press release, AbbVie, NOV 10, 2021, View Source [SID1234595066]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To date, the collaboration has led to novel insights related to biomarkers and therapeutic applications for existing AbbVie programs. This has included the development of novel drug delivery approaches to enhance anti-tumor immune response and incorporating unique 3D screening methodologies for selecting novel therapeutic molecules.
"Our oncology collaboration with the University of Chicago enables us to combine our expertise in understanding the underlying biology in key areas of interest, such as immuno-oncology, oncogenic pathways, and biomarkers of drug sensitivity or disease," said Steve Davidsen, Vice President, Oncology Discovery Research at AbbVie. "This effort drives towards a common goal of accelerating discovery efforts and delivering novel therapies to people living with cancer."
Continuing the intent of the initial research collaboration, the extension of the collaboration is designed to further accelerate and advance medical research in oncology at both organizations.
"Our ambition is that the clinical and translational collaboration between AbbVie and the University of Chicago continues to impact public health positively," said Kunle Odunsi, M.D., Ph.D., AbbVie Foundation Director, University of Chicago Medicine Comprehensive Cancer Center. "The collaboration has created valuable opportunities for scientific exchange and the development of clinical trials for cancer research."
Under the agreement, the organizations will continue working together to advance research in several areas, focusing on oncology, and AbbVie gains an option for an exclusive license to certain University of Chicago discoveries made as part of the collaboration.
"We look forward to more discoveries together in the years to come," said Juan de Pablo, University of Chicago Vice President for National Laboratories, Science Strategy, Innovation, and Global Initiatives. "The extension of our agreement will continue to provide faculty and students with opportunities to work with colleagues at a global biopharmaceutical leader and translate their findings from the lab into the real world. It will enable the kind of preclinical research that is needed to help lay the foundations for better approaches and treatments with the goal to ultimately improve quality of life for patients."